September 19, 2007--Cinacalcet ( Sensipar, Amgen) may emerge as an important new therapeutic option for patients with inoperable parathyroid carcinoma, researchers report. According to the results of ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

HYPERCALCEMIA occurs in a wide variety of diseases (for example, hyperparathyroidism, hypervitaminosis D, sarcoid, cancer, hyperthyroidism and poliomyelitis) 1 and is often responsible for many of the ...

The present report deals with a patient in whom hyperthyroidism was associated with hypercalcemia, nephrocalcinosis and renal insufficiency. With successful treatment of the hyperthyroidism, the ...

Hypercalcemia is a relatively frequent clinical issue. Hyperparathyroidism and malignancy are the most common causes of this condition, accounting for 90% of cases. 1 A 64‑year‑old woman consulted an ...

New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma. Hypercalcemia is caused by many factors in ...

A retrospective review of patients with cancer who received pamidronate or zoledronic acid inpatient at Mayo Clinic for treatment of HCM between January 2018 and January 2024 was conducted. Logistic ...

In this study, we report an FHH patient with typical skeletal manifestations. The patient demonstrated a fracture with transient hypophosphatemia, which confounded the plausible initial diagnosis of ...

A recently published report describes the case of a 61-year-old male patient who experienced antacid-induced hypercalcemia and highlights the importance of performing thorough medication ...

The condition is associated with a death risk similar to that of apparent hypercalcemia. BOSTON—Hidden hypercalcemia is common among new hemodialysis (HD) patients and it is associated with an ...